Compare Medpace Holdings Inc (MEDP) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.34 (market cap $323.80B). The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is far larger — about 19.3× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Vanguard Tax Managed Fund FTSE Developed Markets ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Vanguard Tax Managed Fund FTSE Developed Markets ETF for 131 Days on average.
| MEDP | VEA | |
|---|---|---|
Market Cap | $16.82B | $323.80B |
Volume | 223,093 | 17,001,112 |
Sector | Health | — |
52-Week High | $630.19 | $73.79 |
52-Week Low | $393.42 | $58.90 |
Typical Hold Time | 14 Days | 131 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
VEA trades at $70.21, down 0.07% with bearish technical signals dominating. The ETF shows mixed institutional activity with several firms increasing positions while others reduced exposure. Recent news highlights VEA's competitive advantages including its 0.03% expense ratio and focus on developed markets excluding the U.S. The current technical setup shows oversold conditions with RSI at 28.40 suggesting potential near-term bounce opportunity.
VEA presents a cost-efficient developed markets exposure with strong dividend yield appeal, though technical indicators signal caution. Key risks include global market volatility and currency fluctuations. The ETF's institutional ownership trends and competitive expense ratio support its long-term positioning for investors seeking international diversification beyond U.S. markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
